© Parkinson’s UK, July 2019. Parkinson’s is the operating name of the Parkinson’s Disease Society of the United Kingdom. A charity registered in England and Wales (258197) and in Scotland (SC037554)

Parkinson's UK


27 Feb 2019

Results from a pioneering clinical trials programme that delivered an experimental treatment directly to the brain offer hope that it may be possible to restore the cells damaged in Parkinson’s.

The multimillion-pound study, funded by Parkinson’s UK with support from The Cure Parkinson's Trust and in association with the North Bristol NHS Trust, aimed to investigate w...

31 Jan 2019

Parkinson’s UK has today announced that it is investing a further £1.5million to advance its exciting drug discovery programme to develop novel gene transcription modulators that could stop or slow the progression of Parkinson’s.

The pioneering programme was launched by the charity in March 2018 with Eurofins Selcia Drug Discovery conducting the work as their contract...

24 Sep 2018

Keapstone Therapeutics Limited, a single-asset virtual biotech with an innovative disease-modifying therapeutic approach to motor neuron disease (MND) and Parkinson’s, announces that all drug discovery milestones have been successfully met in order to secure a further £1 million investment from Parkinson’s UK.

This brings the total seed investment in Keapstone to date...

13 Aug 2018

Parkinson’s UK is pleased to announce the release of the next tranche of funding to continue our collaboration with Selcia (part of Eurofins) and Cresset Discovery Services to create novel gene transcription modulators following excellent progress in the first 6 months of the project.  
In March 2018, Parkinson’s UK announced funding of £1.2million to create molecu...

18 Jul 2018

Parkinson’s UK is pleased to announce the release of the next tranche of funding to US company Neurolixis to continue final pre-clinical studies for NLX-112, a novel serotonin 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia.
In January 2018, Parkinson’s UK announced funding of more than $1million in funding to enable the NLX-112 program to mo...

15 May 2018

We're pleased to announce that Keapstone Therapeutics, a spin-out company formed as part of the Parkinson's Virtual Biotech, now has it's own independent website at www.keapstone.com.  

Keapstone Therapeutics is a single asset biotech developing drugs that target the Nrf2 signalling pathway (KEAP1 inhibitors) for two devastating conditions – Parkinson’s and Motor...

Please reload